一种无标记筛选方法及其筛选的FPR1偏向性激动剂在急性肺损伤上的应用
Kinetin Riboside was screened using a label-free screening method. This compound, as an FPR1-biased agonist, can specifically activate the G protein signaling pathway, solving the problem of the lack of drugs for treating acute lung injury in the existing technology and realizing an effective treatment for acute lung injury.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- JINAN UNIVERSITY
- Filing Date
- 2025-11-19
- Publication Date
- 2026-07-17
AI Technical Summary
Currently, there is a lack of specific drugs for the effective treatment of acute lung injury. Existing treatments such as glucocorticoids can only relieve inflammation, but the hospital mortality rate is still as high as 40%. Therefore, there is a need to find more precise treatment drugs.
FPR1-biased agonists were screened using a label-free screening method. Cell signal changes were monitored using the Epic label-free screening instrument and calcium ion indicators. Combined with G protein dissociation and β-arrestin recruitment experiments, kinetin riboside (KR) was screened out. This compound can specifically activate the G protein signaling pathway and inhibit superoxide production and degranulation.
The study identified kinetin nucleosides with therapeutic effects on acute lung injury, which significantly inhibited superoxide production and degranulation, reduced neutrophil infiltration, alleviated lung tissue damage, and decreased mortality.
Smart Images
Figure CN121521807B_ABST